Alzheimer's news - The latest biotech news from Labiotech.eu

Hope for Alzheimer’s patients after Lilly drug results

Jim Cornall — Mon, 17 Jul 2023 16:15:00 +0000

Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […]

The post Hope for Alzheimer’s patients after Lilly drug results appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Partnership to progress neurodegenerative disorder treatments

Jim Cornall — Thu, 13 Jul 2023 09:00:00 +0000

IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]

The post Partnership to progress neurodegenerative disorder treatments appeared first on Labiotech.eu.

FDA approves Alzheimer’s treatment

Jim Cornall — Fri, 07 Jul 2023 09:15:00 +0000

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use. The decision makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression […]

The post FDA approves Alzheimer’s treatment appeared first on Labiotech.eu.

SandboxAQ launches new division to boost drug development

Jim Cornall — Fri, 23 Jun 2023 08:13:19 +0000

After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […]

The post SandboxAQ launches new division to boost drug development appeared first on Labiotech.eu.

Alchemab Therapeutics unveils Alzheimer’s candidate

Jim Cornall — Thu, 22 Jun 2023 09:35:00 +0000

Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France. ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein thought to have a key role in Alzheimer’s disease. […]

The post Alchemab Therapeutics unveils Alzheimer’s candidate appeared first on Labiotech.eu.

‘Clinical trial in a dish’ for Alzheimer’s disease

Jim Cornall — Tue, 13 Jun 2023 12:49:19 +0000

Axol Bioscience Ltd., a pluripotent stem cell technology provider for drug discovery, has signed an agreement with StrataStem to access and commercialize its collection of Alzheimer’s disease (AD) patient samples. Harnessing its stem cell knowledge, Axol will reprogram these patient samples into induced pluripotent stem cells (iPSCs) that can then be differentiated into a wide […]

The post ‘Clinical trial in a dish’ for Alzheimer’s disease appeared first on Labiotech.eu.

Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines

External Contributor — Tue, 13 Jun 2023 12:29:31 +0000

By Dr. Andrea Pfeifer, CEO of AC Immune SA The clinical success we’ve recently seen with two monoclonal antibodies that target the protein amyloid beta (Abeta) has provided hope for patients, a significant boost to the sector but also a strong validation of the “amyloid hypothesis”: removing Abeta plaques is a valid therapeutic strategy for […]

The post Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines appeared first on Labiotech.eu.

How AI can advance research and treatment of CNS disorders

External Contributor — Tue, 13 Jun 2023 12:13:47 +0000

By Xiao Xu, senior research fellow, Cerevance The combination of large-scale biological datasets and developments in artificial intelligence (AI) has revolutionized our understanding and treatment of central nervous system (CNS) disorders. By leveraging AI’s computational power, researchers have been able to interrogate diverse datasets to provide insights into disease mechanisms, discover novel therapeutic compounds, detect […]

The post How AI can advance research and treatment of CNS disorders appeared first on Labiotech.eu.

Six advancements in Alzheimer’s research over the past year

Roohi Mariam Peter — Mon, 12 Jun 2023 11:22:57 +0000

The most common cause of dementia, Alzheimer’s disease, is a brain disorder that is characterized by cognitive decline which often manifests itself through memory loss, feelings of disorientation and difficulty making decisions. Alzheimer’s occurs when there is an excessive accumulation of proteins in the brain, a hallmark feature of the disease. These proteins, namely, amyloid […]

The post Six advancements in Alzheimer’s research over the past year appeared first on Labiotech.eu.

New study reveals Alzheimer’s inflammation protection

Jim Cornall — Tue, 30 May 2023 10:12:39 +0000

A possible explanation has been found in a study for why apoE4, the most significant genetic risk factor associated with Alzheimer’s disease, fails to protect the brain from inflammation.Alzheimer’s disease is characterized by the accumulation of plaques of the amyloid-β protein, chronic inflammation and impaired neuronal function in the brain. The most significant genetic risk […]

The post New study reveals Alzheimer’s inflammation protection appeared first on Labiotech.eu.

Researchers discover genetic variation offers Alzheimer’s disease clues

Jim Cornall — Thu, 25 May 2023 08:15:30 +0000

A new study conducted by researchers at the University of Eastern Finland discovered that the APP A673T genetic variant, which protects against Alzheimer’s disease (AD), alters levels of several proteins and peptides linked to amyloid-beta metabolism in human biofluids and cell culture models, including amyloid beta itself. These new data support the idea that even […]

The post Researchers discover genetic variation offers Alzheimer’s disease clues appeared first on Labiotech.eu.

Cancer implications as new molecule can kill ‘zombie’ cells

Jim Cornall — Mon, 22 May 2023 15:31:52 +0000

Over time, the body’s cells stop working properly and begin to accumulate, which eventually leads to tissues aging. Researchers at the UOC (Universitat Oberta de Catalunya) in Spain, in collaboration with the University of Leicester in the U.K. have discovered a new molecule that is able to destroy these old cells without affecting healthy ones. […]

The post Cancer implications as new molecule can kill ‘zombie’ cells appeared first on Labiotech.eu.

Researchers’ mutation discovery offers new Alzheimer’s hope

Jim Cornall — Tue, 16 May 2023 08:22:19 +0000

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia. Early-onset AD is typically associated with mutations in the genes APP, PSEN1, and PSEN2, leading to a more aggressive form of the disease with atypical symptoms. In contrast, the newly discovered […]

The post Researchers’ mutation discovery offers new Alzheimer’s hope appeared first on Labiotech.eu.

Alzheimer’s drugs could result from immune brain cell discovery

Jim Cornall — Mon, 15 May 2023 14:49:00 +0000

A recent study published in Nature Neuroscience indicates that, contrary to common belief, the immune cells of the brain, known as microglia, are not all the same. Researchers found that a unique microglial subset with unique features and function is important for establishing proper cognitive functions in mice. Evidence for such microglial subsets exists also […]

The post Alzheimer’s drugs could result from immune brain cell discovery appeared first on Labiotech.eu.

Ultra-long protein fibrils could help with early Alzheimer’s diagnosis

Jim Cornall — Tue, 09 May 2023 10:20:52 +0000

The early diagnosis and treatment of dementia such as Alzheimer’s disease is still a big challenge. It is already known that certain proteins in the cerebrospinal fluid can be used to diagnose Alzheimer’s disease. However, the current detection methods for such biomarkers by means of biochemical tests can only confirm and quantify the presence of […]

The post Ultra-long protein fibrils could help with early Alzheimer’s diagnosis appeared first on Labiotech.eu.

Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline

Jim Cornall — Wed, 03 May 2023 15:07:19 +0000

Eli Lilly and Company has announced positive results of the TRAILBLAZER-ALZ 2 phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease Rating Scale (iADRS). The primary endpoint of […]

The post Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline appeared first on Labiotech.eu.

6 new vaccines being developed for difficult-to-treat diseases

Willow Shah-Neville — Wed, 12 Apr 2023 13:01:28 +0000

There are several promising new vaccine candidates being developed for complex diseases that historically have been extremely difficult to find treatments and cures for. The development of these new vaccines could eventually lead to breakthrough treatments for diseases such as Alzheimer’s disease, HIV, Parkinson’s disease, Lyme disease, and breast cancer. According to the World Health […]

The post 6 new vaccines being developed for difficult-to-treat diseases appeared first on Labiotech.eu.

Alzamend pushing ahead with Alzheimer’s vaccine trial

Jim Cornall — Tue, 04 Apr 2023 10:15:21 +0000

Alzamend Neuro, Inc. has announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type. The purpose of the trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of Alzamend Neuro’s ALZN002 compared with that of placebo in […]

The post Alzamend pushing ahead with Alzheimer’s vaccine trial appeared first on Labiotech.eu.

€260M fund addresses dementia investment shortfall

Jim Cornall — Fri, 31 Mar 2023 09:56:14 +0000

EQT Life Sciences has closed its inaugural LSP Dementia Fund, raising approximately €260 million ($283 million) in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of €100 million ($108.9 million). The LSP Dementia Fund is dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies […]

The post €260M fund addresses dementia investment shortfall appeared first on Labiotech.eu.

5 advancements in Down syndrome research over the past year

Roohi Mariam Peter — Tue, 21 Mar 2023 10:35:21 +0000

It was in 1959 when an extra chromosome on the 21st pair in the human cell was discovered by French geneticist Jerome Jean Louis Marie Lejeune. This was followed by research in the discipline of cytogenetics – the study of chromosomes. This chromosomal aberration which affects around one in 1000 live births worldwide, is called […]

The post 5 advancements in Down syndrome research over the past year appeared first on Labiotech.eu.